LFA-1 inhibitors (Tanabe/Novartis)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameLFA-1 inhibitors (Tanabe/Novartis)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLeukocyte adhesion glycoprotein LFA-1 alpha antagonists
TargetsLeukocyte adhesion glycoprotein LFA-1 alpha
Therapy Area/IndicationsRejection of organ transplantationAutoimmune DiseasesPsoriasis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryWestern EuropeJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTanabe Seiyaku Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma AgTanabe Seiyaku Co Ltd
Active IndicationsN/A
Inactive IndicationsRejection of organ transplantationAutoimmune DiseasesPsoriasis +[5] 

Other Information

ATC CodeN/A
Related LinksN/A